| abstract |
The invention discloses a novel liver targeting adefovir prodrug. The medicament may be selectively hydrolyzed in liver in vivo to produce adefovir, an antiviral active component, further reduce redistribution and accumulation of adefovir in kidney, and avoid nephrotoxicity. The compound may be used in manufacture of medicaments for anti-virus, especially type B hepatitis virus. |